Clinical Trial Update: Afrezza® Dosing Optimization Study [Phase 4]

View source ↗

Summary

Phase 4 trial update on Afrezza dosing optimization completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Afrezza (Technosphere insulin)

Snippet

Sponsor: Mannkind Corporation | Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED | Results posted: 2023-09-18